CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Over the last 20 years, we’ve seen major strides in the treatment options for major depressive disorder. We now understand that depression isn’t the same for everyone. The idea is to identify ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...